NCT02391194View on ClinicalTrials.gov

Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Breast Cancer
Interventions
DRUG

AVB-620

Trial Locations (3)

92093

Moores UC San Diego Cancer Center, La Jolla

94115

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

94305

Stanford Hospitals and Clinics, Stanford

Sponsors
All Listed Sponsors
lead

Avelas Biosciences, Inc.

INDUSTRY

NCT02391194 - Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery | Biotech Hunter | Biotech Hunter